OOIR: Observatory of International Research

Papers

(The H4-Index of Trends in Pharmacological Sciences is 52. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Subscription and Copyright Information	918
Shearing of surface mucin saps tumor cell strength	581
Subscription and Copyright Information	454
Advisory Board and Contents	234
Subscription and Copyright Information	232
Subscription and Copyright Information	198
Muscarinic receptors: from clinic to bench to clinic	178
Subscription and Copyright Information	165
DOT1L: orchestrating methylation-dependent radiotheRAPy responses via BRCA1	163
Swinging the SWI/SNF complexes for cancer therapy	158
Monitoring neurodegeneration through brain-derived extracellular vesicles in biofluids	149
Advancing chemical carcinogenicity prediction modeling: opportunities and challenges	149
Ensifentrine (Ohtuvayre™) for chronic obstructive pulmonary disease	144
Compstatins: the dawn of clinical C3-targeted complement inhibition	140
Structural asymmetry in FGF23 signaling	129
Peptides as a therapeutic strategy against Klebsiella pneumoniae	127
Direct in vivo CAR T cell engineering	123
Targeting complement in neurodegeneration: challenges, risks, and strategies	121
Structural pharmacology and mechanisms of GLP-1R signaling	113
Therapeutic inhibition of ferroptosis in neurodegenerative disease	97
Nemolizumab (Nemluvio®) for prurigo nodularis	97
A smart hospital-driven approach to precision pharmacovigilance	89
Chemically modified neoantigen-based immunotherapy for targeting KRASG12C-driven tumors	89
Advisory Board and Contents	87
Genetically engineered loaded extracellular vesicles for drug delivery	87

Leveraging human microbiomes for disease prediction and treatment	87
Phenotypic approaches for CNS drugs	84
Ribosome-directed cancer therapies: the tip of the iceberg?	84
Optogenetic engineering for precision cancer immunotherapy	81
Mechanistic considerations for adenosine-lidocaine-magnesium (ALM) in controlling coagulopathy	80
Advisory Board and Contents	80
Advisory Board and Contents	79
The B7-H3 (CD276) pathway: emerging biology and clinical therapeutics	76
A deep dive into degrader-induced protein-protein interfaces	75
Emerging strategies for beta cell transplantation to treat diabetes	74
Engineering ACE2 decoy receptors to combat viral escapability	73
A perspective on psychedelic teratogenicity: the utility of zebrafish models	72
siRNA drug Leqvio (inclisiran) to lower cholesterol	70
HSV-1 as a gene delivery platform for cancer gene therapy	66
Close to a year in TIPS’ saddle – I am optimistic	65
Emerging approaches to induce immune tolerance to therapeutic proteins	64
Bimetallic nanoadjuvants for cancer vaccines	64
Subscription and Copyright Information	64
GPR35, ally of the anti-ischemic ATPIF1-ATP synthase interaction	61
Deubiquitinating enzymes as therapeutic targets in diabetic nephropathy	60
Thriving as members of under-represented groups in pharmacology-related careers	60
Advisory Board and Contents	59
Subscription and Copyright Information	58
Suzetrigine for moderate to severe acute pain	57
Autologous, allogeneic, in vivo CAR for autoimmune diseases	53
Mentoring future science leaders to thrive	53
Alzheimer’s therapeutic development: shifting neurodegeneration to neuroregeneration	52